ProKidney (NASDAQ:PROK) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

ProKidney (NASDAQ:PROK) released its earnings results on Monday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Zacks reports. The firm had revenue of $0.08 million for the quarter.

ProKidney Trading Up 5.7 %

NASDAQ:PROK opened at $1.04 on Tuesday. The stock has a 50 day moving average of $1.48 and a two-hundred day moving average of $1.77. ProKidney has a 12 month low of $0.94 and a 12 month high of $4.44. The firm has a market cap of $303.33 million, a P/E ratio of -1.89 and a beta of 1.38.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.